← INmune Bio, Inc. (INMB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
INmune Bio, Inc. (INMB)
Biological Products, (No Diagnostic Substances) · market cap $56M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
INmune Bio (INMB) is a clinical-stage biotech with two Phase 2 assets: INKmune (cancer) and XPro1595 (Alzheimer's disease). The company carries a ~$55M market cap, $21.4M in cash providing roughly 18–19 months of runway, and has generated zero revenue across five reported fiscal years.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-10-31Regulatoryimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| INKmune | Phase 2 | Cancer |
| XPro1595 | Phase 2 | Alzheimer Disease |
Price & technical context
3-month
-0.5%
6-month
+56.8%
12-month
-8.0%
52-wk range
$1.12–$2.51
vs 50-day MA
-13.3%
vs 200-day MA
+13.0%
Realized vol
72.2%
Max drawdown
-89.3%
Daily closes through 2026-10-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INMB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.